The final denial of ANI's post-trial motion removes a major overhang on CGON shares — the risk of having to pay perpetual royalties on CG0070 sales. With the contract intact and no royalty obligation, CGON's economics on its lead asset are significantly improved. Monitor for any appeal by ANI (not mentioned in the opinion) and for CG0070 clinical/commercial milestones.
Price Chart
Executive Summary
The Delaware Superior Court denied ANI Pharmaceuticals' post-trial motion for a new trial and judgment as a matter of law, upholding the jury's verdict that the invalidation of CG Oncology's perpetual royalty obligation under Brulotte did not materially alter the economic substance of the 2010 agreement. The ruling confirms that CG Oncology is not required to pay royalties on CG0070 sales after patent expiration, removing a significant contingent liability and preserving the remainder of the contract (including CG's 19.9% equity stake in CGON, board seat, and sublicensing revenue share).
Court Ruling Details
Key Facts
- Jury found that invalidating the perpetual royalty provision did not materially adversely affect ANI, so the contract survives via severability.
- CG Oncology retains all non-royalty benefits of the 2010 agreement: 19.9% equity stake, board seat, 30% sublicensing revenue share, and patent maintenance cost shifting.
- ANI's motion for a new trial and judgment as a matter of law was DENIED in full.
- The ruling is final and appealable; no stay was mentioned in the opinion.
- CG0070 is an oncolytic virus for bladder cancer — a key pipeline asset for CG Oncology.
Financial Impact
Removes perpetual royalty obligation on CG0070 net sales (5% running royalty) that could have been material if CG0070 achieves commercial success. No dollar amount was stated in the opinion.
Risk Factors
- ANI may appeal the ruling to the Delaware Supreme Court, though the opinion notes no pending appeal or stay.
- CG0070 remains an unapproved drug — clinical and regulatory risk persists.
- The 19.9% equity stake held by ANI could be sold, creating overhang.
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-a3d1f282d5-CGON |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 3 | $61.93 | awaiting T+20 | — | $61.56 (−0.60%) |
Oct 15, 2026 11d ago | 144 | $59.85 | awaiting T+20 | — | $61.56 (+2.86%) |
Oct 12, 2026 14d ago | Institutional Cluster | $63.13 | awaiting T+20 | — | $61.56 (−2.49%) |
Aug 6, 2026 11w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $61.56 (+17.76%) |
Aug 6, 2026 11w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $61.56 (+17.76%) |
Jul 27, 2026 12w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $61.56 (−15.23%) |
Jul 17, 2026 14w ago | Insider Cluster | $70.19 $77.11 | ▲ +9.86% | ▲ +5.74% | $61.56 (−12.30%) |
Jul 16, 2026 14w ago | Court Ruling | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $61.56 (−14.32%) |
Jun 24, 2026 17w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $61.56 (−15.49%) |
Jun 22, 2026 18w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $61.56 (−6.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers